Does anyone else wonder why they didn't extend the term of treatment in P2b? Make it 16 weeks? I guess one reason would be the ability to compare 12 weeks of data across 2a and 2b, but they could do that anyway. I wonder if the 200 mg dose effectiveness plateaued by 12 weeks?
Anyway, just thinking out loud.
Anyway, just thinking out loud.